Clomid Plus Gonadotropin Versus Letrozole Plus Gonadotropin in Stimulation of Infertile Women

Abstract

A comparative prospective study was conducted in the High Institute of Infertility Diagnosis and Assisted Reproductive Technologies/Al-Nahrain University, from September 2019 to March 2020. The study included 60 women who attended the infertility clinic of the High Institute of Infertility Diagnosis and Assisted Reproductive Technologies/Al-Nahrain University. Follitropin Alfa ampoules 75 IU, subcutaneous, from 7th day of menstrual cycle and the dose was adapted according to the ovarian response to the dose of treatment. Other twenty females were treated with Femara (Letrozole). The study showed that the highest mean of LH (in the day of triggering of the follicle) was recorded in women under Clomid +FSH treatment (13.52±7.22 mlU/ml) followed the control group (10.1±4.21 mlU/ml) and the lowest mean was in women received Letrozole+ FSH (8.67±4.54 mlU/ml). The study also demonstrated that the mean of E2 was elevated significantly in women under Clomid +FSH treatment (280.5±191.4 pg/ml) followed by in women received Letrozole+ FSH (214.2±141.4 pg/ml) and the lowest mean was in the control group (164.7±102.7 pg/ml). The maximum mean of progesterone was recorded in in women under Clomid +FSH treatment (4.15±3.2 ng/ml) followed by women received Letrozole+ FSH and the control group.